Pulmicort Turbuhaler, 1 piece, 200 mcg/dose, dosed powder for inhalation
To minimize the risk of fungal infection of the oropharynx, the patient should be instructed to thoroughly rinse the mouth with water after each inhalation of the drug.
Co-administration of budesonide with ketoconazole, itraconazole or other potential CYP3A4 inhibitors should be avoided. If budesonide and ketoconazole or itraconazole or other potential CYP3A4 inhibitors have been prescribed, the time between doses should be increased to the maximum possible.
Due to the possible risk of weakening pituitary-adrenal function, special attention should be paid to patients who are transferred from oral corticosteroids to taking Pulmicort®. Also, special attention should be paid to patients who have taken high doses of GCS, or who have been receiving the highest recommended doses of inhaled GCS for a long time. In stressful situations, these patients may exhibit signs and symptoms of adrenal insufficiency. In case of stress or in cases of surgical intervention, it is recommended to carry out additional therapy with systemic corticosteroids.
Particular attention should be paid to patients who are transferred from systemic to inhaled GCS (Pulmicort® Turbuhaler®), or in cases where a violation of the pituitary-adrenal function can be expected. In such patients, the dose of systemic corticosteroids should be reduced with extreme caution and the hormonal function of the adrenal glands should be monitored. Patients may also need to be prescribed oral corticosteroids during stressful situations, such as trauma, surgery, etc.
When switching from oral corticosteroids to Pulmicort® Turbuhaler®, patients may experience previously observed symptoms such as muscle pain or joint pain. In such cases, a temporary increase in the dose of oral corticosteroids may be necessary. In rare cases, symptoms such as fatigue, headache, nausea and vomiting may occur, indicating systemic insufficiency of GCS.
Replacing oral corticosteroids with inhaled ones sometimes leads to the manifestation of existing allergies (for example, rhinitis and eczema), which were previously treated with systemic drugs.
In children and adolescents receiving treatment with corticosteroids (regardless of the method of delivery) for an extended period, it is recommended to regularly monitor growth parameters.
Patients should be instructed to contact their physician if the effectiveness of therapy with short-acting bronchodilators decreases, because An independent increase in the frequency of use of the drug may lead to a delay in the prescription of adequate treatment. In case of sudden deterioration of the condition, it is necessary to consider the possibility of a course of treatment with oral corticosteroids.
Impact on the ability to drive a car or use other machinery.
Pulmicort® Turbuhaler® does not affect the ability to drive a car or use other machinery.
Instructions for the correct use of Turbuhaler®
The drug contained in Turbuhaler® enters the patient's respiratory tract along with air flows when active inhalation is performed through the Turbuhaler® mouthpiece.
Attention:
it is important to convince the patient to carefully read the instructions for using Pulmicort® Turbuhaler®.
To be sure that the optimal dose of the drug has reached the lungs, you need to inhale deeply and forcefully through the Turbuhaler® mouthpiece.
Under no circumstances should you exhale through the mouthpiece.
After inhaling the required dose of the drug, rinse your mouth with water in order to minimize the risk of fungal infection of the oropharynx.
How to use Pulmicort® Turbuhaler®
Turbuhaler® is a multi-dose inhaler that allows you to dose and inhale the drug in very small doses. When the patient inhales, Turbuhaler® powder is delivered to the lungs. Therefore, it is important that the patient inhales forcefully and deeply through the mouthpiece.
Turbuhaler® is very easy to use. You just need to follow the instructions given below:
1. Unscrew and remove the cap.
2. Keep the inhaler upright
, dispenser down. Load the dose into the inhaler by turning the dispenser counterclockwise until it stops, and then turn the dispenser to its original position until it clicks.
3. Exhale
.
Do not exhale through
the mouthpiece.
Before exhaling, remove the inhaler from your mouth.
4. Gently squeeze the mouthpiece between your teeth, purse your lips and inhale deeply and forcefully
through the mouth. The mouthpiece should not be chewed or squeezed tightly with your teeth.
If inhalation of more than one dose is required, repeat steps 2–5.
5. Close the inhaler with the cap.
6. Rinse your mouth with water.
IMPORTANT!
Never exhale through the mouthpiece. Always cap the inhaler tightly after use.
Since the amount of powder inhaled is very small, the patient may not be able to taste the powder after inhalation. However, if he followed the instructions, he can be sure that he inhaled the required dose of the drug.
Cleaning
Clean the outside of the mouthpiece regularly (once a week) with a dry cloth.
Do not use water or other liquids to clean the mouthpiece.
How do you know if your inhaler is empty?
When a red indicator appears in the dose window, it means there are approximately 20 doses left in the inhaler. The inhaler is empty when the red mark reaches the bottom edge of the dose indicator window.
The sound heard when the inhaler is shaken is produced by the drying agent, not the medication.
Pulmicort Turbuhaler (portion d/ing. 100 mcg/dose 200 doses)
A country
Sweden
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Budesonide
Compound
The active substance is budesonide.
pharmachologic effect
Pharmacological action - anti-inflammatory, antiallergic. Inhibits the synthesis of leukotrienes and PGs, inhibits the production of cytokines, prevents the migration and activation of inflammatory cells, increases the sensitivity of beta-adrenergic receptors of bronchial smooth muscles. The part that enters the gastrointestinal tract is almost completely destroyed during the “first pass” through the liver. Has high systemic clearance. It is excreted in the urine, and partially in bile in the form of inactive metabolites. Resorption of budesonide from ointment occurs more slowly than from cream, and the effect lasts longer, so it is preferable to use ointment for the treatment of chronic processes. It has local vasoconstrictor properties, normalizes vascular permeability, stabilizes lysosomal membranes and inhibits cell migration into inflammatory tissue.
Indications for use
Bronchial asthma, chronic obstructive bronchitis, atopic dermatitis, psoriasis, eczema.
Mode of application
Inhalation (inhalation from a turbuhaler). Adults: initial dose 400-800 mcg per day in 2 divided doses (morning and evening); with previous treatment with oral glucocorticoids, the initial daily dose can be increased to 1.6 mg. Children over 6 years of age: initial dose - 200 mcg 2 times a day. The maximum dose is 400 mcg per day; after previous therapy with oral glucocorticoids - up to 800 mcg per day.
Interaction
Adrenergic agonists enhance the effect. Inhibitors of cytochrome P450 enhance the effect. Increases the effect of cardiac glycosides. Saluretics increase potassium excretion. Cimetidine slows down elimination.
Side effect
Locally: hemorrhages, skin atrophy, superinfection, dermatitis, folliculitis, hypopigmentation, striae, hypertrichosis, papular dermatitis, burning sensation, itching, systemic effects of glucocorticoids (with prolonged use of an occlusive dressing); For inhalations: dysphonia, sore throat, irritation of the larynx, cough.
Contraindications
Hypersensitivity, pregnancy, breastfeeding (breastfeeding should be stopped during treatment); for topical use: viral, fungal, bacterial (including tuberculosis) skin infections, lichen vulgaris, rosacea; for inhalation use: active form of pulmonary tuberculosis, fungal infections of the respiratory system.
Overdose
No data.
special instructions
Ointment and cream should not be applied to mucous membranes (avoid contact with eyes). With prolonged use, candidiasis may develop.
Dispensing conditions in pharmacies
On prescription
Pulmicort Turbuhaler (portion d/ing. 200 mcg/dose 100 doses)
A country
Sweden
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Budesonide
Compound
The active substance is budesonide.
pharmachologic effect
Pharmacological action - anti-inflammatory, antiallergic. Inhibits the synthesis of leukotrienes and PGs, inhibits the production of cytokines, prevents the migration and activation of inflammatory cells, increases the sensitivity of beta-adrenergic receptors of bronchial smooth muscles. The part that enters the gastrointestinal tract is almost completely destroyed during the “first pass” through the liver. Has high systemic clearance. It is excreted in the urine, and partially in bile in the form of inactive metabolites. Resorption of budesonide from ointment occurs more slowly than from cream, and the effect lasts longer, so it is preferable to use ointment for the treatment of chronic processes. It has local vasoconstrictor properties, normalizes vascular permeability, stabilizes lysosomal membranes and inhibits cell migration into inflammatory tissue.
Indications for use
Bronchial asthma, chronic obstructive bronchitis, atopic dermatitis, psoriasis, eczema.
Mode of application
Inhalation (inhalation from a turbuhaler). Adults: initial dose 400-800 mcg per day in 2 divided doses (morning and evening); with previous treatment with oral glucocorticoids, the initial daily dose can be increased to 1.6 mg. Children over 6 years of age: initial dose - 200 mcg 2 times a day. The maximum dose is 400 mcg per day; after previous therapy with oral glucocorticoids - up to 800 mcg per day.
Interaction
Adrenergic agonists enhance the effect. Inhibitors of cytochrome P450 enhance the effect. Increases the effect of cardiac glycosides. Saluretics increase potassium excretion. Cimetidine slows down elimination.
Side effect
Locally: hemorrhages, skin atrophy, superinfection, dermatitis, folliculitis, hypopigmentation, striae, hypertrichosis, papular dermatitis, burning sensation, itching, systemic effects of glucocorticoids (with prolonged use of an occlusive dressing); For inhalations: dysphonia, sore throat, irritation of the larynx, cough.
Contraindications
Hypersensitivity, pregnancy, breastfeeding (breastfeeding should be stopped during treatment); for topical use: viral, fungal, bacterial (including tuberculosis) skin infections, lichen vulgaris, rosacea; for inhalation use: active form of pulmonary tuberculosis, fungal infections of the respiratory system.
Overdose
No data.
special instructions
Ointment and cream should not be applied to mucous membranes (avoid contact with eyes). With prolonged use, candidiasis may develop.
Dispensing conditions in pharmacies
On prescription
Pulmicort Turbuhaler powder for ing 100mcg/dose 200doses
Active substance
Budesonide
pharmachologic effect
Glucocorticosteroid for local use.
Budesonide is a glucocorticosteroid with strong local anti-inflammatory effects.
The exact mechanism of action of glucocorticosteroids in the treatment of bronchial asthma is not completely clear. Anti-inflammatory effects, such as inhibition of the release of inflammatory mediators and cytokine-mediated immune responses, are perhaps most important. The affinity of budesonide for glucocorticosteroid receptors is 15 times higher than that of prednisolone.
The anti-inflammatory effect of budesonide is mediated by a decrease in the degree of airway obstruction during the early and late allergic response. Budesonide reduces airway reactivity in response to inhaled histamine and methacholine.
The sooner treatment with budesonide is started after the diagnosis of persistent bronchial asthma is made, the greater the improvement in lung function should be expected.
A dose-dependent effect on the content of cortisone in plasma and urine while taking Pulmicort Turbuhaler was shown. At recommended doses, the drug has significantly less effect on adrenal function than prednisone at a dose of 10 mg as shown in ACTH tests.
The use of budesonide at a dose of up to 400 mcg/day in children over 3 years of age did not lead to systemic effects. Biochemical signs of a systemic effect of the drug may occur when taking the drug at a dose of 400 to 800 mcg/day. When the dose exceeds 800 mcg/day, systemic effects of the drug are common.
The use of glucocorticosteroids for the treatment of bronchial asthma may cause growth impairment.
The results of observations of children and adolescents receiving budesonide for a long period (up to 11 years) showed that the growth of patients reaches the expected normative indicators for adults. Therapy with inhaled budesonide 1 or 2 times a day has been shown to be effective in preventing exercise-induced asthma.
Indications
- bronchial asthma requiring maintenance therapy with glucocorticosteroids to control the inflammatory process.
- chronic obstructive pulmonary disease (COPD).
Before use, consultation with a specialist is required.
Method of use, storage mode, contraindications and side effects are indicated in the instructions
